Valeant CEO J. Michael Pearson and the company's largest shareholder, Bill Ackman, have been trying to propel Allergan's board toward deal negotiations ever since they announced their first unsolicited bid back in April. And now, they're adding a little extra incentive.
In the midst of an ongoing reorganization, contract developer AMRI has made another buy in manufacturing, signing a deal to scoop up CMO OsoBio for $110 million in cash.
German researcher Evotec has signed a deal to pay as much as $5.3 million for specialty CRO Euprotec, a company focused on anti-infective drug discovery.
Retrophin, the biotech helmed by hedge funder Martin Shkreli, leapt more than 25% after buying the rights to another drug with the potential to treat a rare disease.
GlaxoSmithKline has already made some moves to sell off some of its older meds. But now, it's making more that could end up much, much bigger.
Citing "usually well-informed sources," the Financial Times reports that Shire is considering a $4 billion bid for rare disease specialist NPS Pharma, a deal that would bolster the company's last blockbuster acquisition and perhaps get it out of rivals' crosshairs.
Back in February, notorious rebel investor Carl Icahn promoted a Forest deal to sell itself to Actavis as a momentous victory for shareholders. But while investors may have agreed with the principle of a transaction, it turns out not all of them were so happy with the way Forest made the sale--and to whom.
Vivus has been through a lot over the past year, including an all-out proxy war, a myriad of exec exits and, most recently, a generic threat from Actavis to its flailing obesity drug Qsymia. And now? It appears to have an interested buyer, according to a regulatory filing.
Jordan's Hikma Pharmaceuticals has sewn up its deal to buy Bedford Laboratories, a struggling Ohio-based maker of injectable drugs owned by the Boehringer Ingelheim unit Ben Venue Laboratories.
After rumors circulated that Stryker would lay down a bid for orthopedics rival Smith & Nephew, Stryker CEO Kevin Lobo confirmed that his company is considering a deal--even if it doesn't plan to make an offer anytime soon.